These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 15487888)
1. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for immunotherapy in epithelial ovarian cancer. Tammela J; Jungbluth AA; Qian F; Santiago D; Scanlan MJ; Keitz B; Driscoll D; Rodabaugh K; Lele S; Old LJ; Odunsi K Cancer Immun; 2004 Oct; 4():10. PubMed ID: 15487888 [TBL] [Abstract][Full Text] [Related]
2. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Odunsi K; Jungbluth AA; Stockert E; Qian F; Gnjatic S; Tammela J; Intengan M; Beck A; Keitz B; Santiago D; Williamson B; Scanlan MJ; Ritter G; Chen YT; Driscoll D; Sood A; Lele S; Old LJ Cancer Res; 2003 Sep; 63(18):6076-83. PubMed ID: 14522938 [TBL] [Abstract][Full Text] [Related]
3. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in epithelial ovarian cancer. Garg M; Chaurasiya D; Rana R; Jagadish N; Kanojia D; Dudha N; Kamran N; Salhan S; Bhatnagar A; Suri S; Gupta A; Suri A Clin Cancer Res; 2007 Mar; 13(5):1421-8. PubMed ID: 17332284 [TBL] [Abstract][Full Text] [Related]
4. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer. Tammela J; Uenaka A; Ono T; Noguchi Y; Jungbluth AA; Mhawech-Fauceglia P; Qian F; Schneider S; Sharma S; Driscoll D; Lele S; Old LJ; Nakayama E; Odunsi K Int J Oncol; 2006 Oct; 29(4):903-10. PubMed ID: 16964386 [TBL] [Abstract][Full Text] [Related]
5. A-kinase anchoring protein 3 messenger RNA expression correlates with poor prognosis in epithelial ovarian cancer. Sharma S; Qian F; Keitz B; Driscoll D; Scanlan MJ; Skipper J; Rodabaugh K; Lele S; Old LJ; Odunsi K Gynecol Oncol; 2005 Oct; 99(1):183-8. PubMed ID: 16005946 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of mammaglobin B in epithelial ovarian carcinomas. Tassi RA; Bignotti E; Rossi E; Falchetti M; Donzelli C; Calza S; Ravaggi A; Bandiera E; Pecorelli S; Santin AD Gynecol Oncol; 2007 Jun; 105(3):578-85. PubMed ID: 17343903 [TBL] [Abstract][Full Text] [Related]
7. Expression of synovial sarcoma X (SSX) antigens in epithelial ovarian cancer and identification of SSX-4 epitopes recognized by CD4+ T cells. Valmori D; Qian F; Ayyoub M; Renner C; Merlo A; Gnjatic S; Stockert E; Driscoll D; Lele S; Old LJ; Odunsi K Clin Cancer Res; 2006 Jan; 12(2):398-404. PubMed ID: 16428478 [TBL] [Abstract][Full Text] [Related]
8. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Bignotti E; Todeschini P; Calza S; Falchetti M; Ravanini M; Tassi RA; Ravaggi A; Bandiera E; Romani C; Zanotti L; Tognon G; Odicino FE; Facchetti F; Pecorelli S; Santin AD Eur J Cancer; 2010 Mar; 46(5):944-53. PubMed ID: 20060709 [TBL] [Abstract][Full Text] [Related]
9. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer]. Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380 [TBL] [Abstract][Full Text] [Related]
10. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms. Wang P; Wu X; Chen W; Liu J; Wang X Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312 [TBL] [Abstract][Full Text] [Related]
11. CABYR is a novel cancer-testis antigen in lung cancer. Luo C; Xiao X; Liu D; Chen S; Li M; Xu A; Liu J; Gao S; Wu S; He D Clin Cancer Res; 2007 Feb; 13(4):1288-97. PubMed ID: 17317841 [TBL] [Abstract][Full Text] [Related]
14. Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum. Jäger D; Unkelbach M; Frei C; Bert F; Scanlan MJ; Jäger E; Old LJ; Chen YT; Knuth A Cancer Immun; 2002 Jun; 2():5. PubMed ID: 12747750 [TBL] [Abstract][Full Text] [Related]
15. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723 [TBL] [Abstract][Full Text] [Related]
16. Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. Sharma P; Gnjatic S; Jungbluth AA; Williamson B; Herr H; Stockert E; Dalbagni G; Donat SM; Reuter VE; Santiago D; Chen YT; Bajorin DF; Old LJ Cancer Immun; 2003 Dec; 3():19. PubMed ID: 14680360 [TBL] [Abstract][Full Text] [Related]
17. Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer. Campos X; Muñoz Y; Selman A; Yazigi R; Moyano L; Weinstein-Oppenheimer C; Lara HE; Romero C Gynecol Oncol; 2007 Jan; 104(1):168-75. PubMed ID: 16935322 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients. Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446 [TBL] [Abstract][Full Text] [Related]
19. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma]. Zhang MZ; Qiao YH; Suo ZH Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831 [TBL] [Abstract][Full Text] [Related]
20. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Wang L; Ma J; Liu F; Yu Q; Chu G; Perkins AC; Li Y Gynecol Oncol; 2007 Jun; 105(3):695-702. PubMed ID: 17368732 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]